Stifel Financial
AKBA icon

Stifel Financial’s Akebia Therapeutics AKBA Stock Holding History

Stifel Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,008
Closed -$43K – 3014
2019
Q3 		$43K Buy
+11,008
New +$47.2K ﹤0.01% 2803
2019
Q2 		– Sell
-10,974
Closed -$90K – 2958
2019
Q1 		$90K Sell
10,974
-62
-0.6% -$425 ﹤0.01% 2707
2018
Q4 		$61K Buy
+11,036
New +$86.4K ﹤0.01% 2600
2016
Q2 		– Sell
-445,000
Closed -$4.3M – 2507
2016
Q1 		$4.3M Sell
445,000
-100
-0% -$811 0.02% 602
2015
Q4 		$4.3M Hold
445,100
– – 0.02% 621
2015
Q3 		$4.3M Buy
445,100
+396
+0.1% +$3.63K 0.02% 572
2015
Q2 		$10.3M Hold
444,704
– – 0.05% 358
2015
Q1 		$11.1M Sell
444,704
-100
-0% -$1.06K 0.06% 366
2014
Q4 		$11.6M Sell
444,804
-100
-0% -$1.43K 0.06% 360
2014
Q3 		$12.4M Hold
444,904
– – 0.11% 236
2014
Q2 		$12.4M Buy
+444,904
New +$10.7M 0.11% 246

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial's AKBA Position: Q4 2019 in Review

Stifel Financial sold out of Akebia Therapeutics (AKBA) in Q4 2019, closing a stake of 11,008 shares — an estimated $43K sold.

Stifel Financial first reported a position in AKBA in Q2 2014 and held it in 11 quarters. The position peaked at $12.4M in Q2 2014. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Stifel Financial reported no remaining Akebia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Stifel Financial sold 11,008 Akebia Therapeutics shares in Q4 2019, an estimated $43K.
  • Stifel Financial first reported a position in Akebia Therapeutics in Q2 2014 and held it in 11 quarters.
  • Stifel Financial's Akebia Therapeutics position peaked at $12.4M in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Stifel Financial's 13F filing for Q4 2019, filed 13 Feb 2020.